公开(公告)号：US20240052419A1

公开(公告)日：2024-02-15

申请号：US17818944

申请日：2022-08-10

Applicant: GUARDANT HEALTH, INC.

Inventor： Helmy ELTOUKHY ,  AmirAli TALASAZ ,  Bahram Ghaffarzadeh KERMANI ,  Nnamdi IHUEGBU

IPC: C12Q1/6886 ,  C12Q1/6874

CPC classification number: C12Q1/6886 ,  C12Q1/6874

Abstract: This disclosure provides, among other things, methods for generating and applying therapeutic interventions. The methods involve, for example, (a) sequencing polynucleotides from cancer cells from a subject; (b) identifying and quantifying somatic mutations in the polynucleotides; (c) developing a profile of tumor heterogeneity in the subject indicating the presence and relative quantity of a plurality of the somatic mutations in the polynucleotides, wherein different relative quantities indicates tumor heterogeneity; and (d) determining a therapeutic intervention for a cancer exhibiting the tumor heterogeneity, wherein the therapeutic intervention is effective against a cancer having the profile of tumor heterogeneity determined.

公开(公告)号：US20230313315A1

公开(公告)日：2023-10-05

申请号：US18156890

申请日：2023-01-19

Applicant: GUARDANT HEALTH, INC.

Inventor： Stefanie Ann Ward MORTIMER ,  AmirAli TALASAZ ,  Darya CHUDOVA ,  Helmy ELTOUKHY

IPC: C12Q1/6886 ,  C12Q1/6806 ,  G16H50/20 ,  G16H50/30 ,  C12Q1/6869 ,  C12M1/34 ,  G16B30/10 ,  G16B20/20 ,  C12M1/00 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12M1/00 ,  C12M1/34 ,  C12Q1/6806 ,  C12Q1/6869 ,  G01N33/57407 ,  G16B20/20 ,  G16B30/10 ,  G16H50/20 ,  G16H50/30 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/166

Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.

公开(公告)号：US20230272468A1

公开(公告)日：2023-08-31

申请号：US18316864

申请日：2023-05-12

Applicant: GUARDANT HEALTH, INC.

Inventor： AmirAli TALASAZ ,  Helmy ELTOUKHY ,  Stefanie Ann Ward MORTIMER

IPC: C12Q1/6869 ,  C12Q1/6886

CPC classification number: C12Q1/6869 ,  C12Q1/6886 ,  G16B15/00

Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.

公开(公告)号：US20230083814A1

公开(公告)日：2023-03-16

申请号：US18047979

申请日：2022-10-19

Applicant: GUARDANT HEALTH, INC.

Inventor： Stefanie Ann Ward MORTIMER ,  AmirAli TALASAZ ,  Darya CHUDOVA ,  Helmy ELTOUKHY

IPC: C12Q1/6886 ,  C12M1/34 ,  C12M1/00 ,  G01N33/574 ,  G16B30/10 ,  G16B20/20 ,  C12Q1/6806 ,  C12Q1/6869 ,  G16H50/30 ,  G16H50/20

Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.

公开(公告)号：US20220325360A1

公开(公告)日：2022-10-13

申请号：US17837375

申请日：2022-06-10

Applicant: GUARDANT HEALTH, INC.

Inventor： Stefanie Ann Ward MORTIMER ,  AmirAli TALASAZ ,  Darya CHUDOVA ,  Helmy ELTOUKHY

IPC: C12Q1/6886 ,  C12M1/34 ,  C12M1/00 ,  G01N33/574 ,  G16B30/10 ,  G16B20/20 ,  C12Q1/6806 ,  C12Q1/6869 ,  G16H50/30 ,  G16H50/20

Abstract: Disclosed herein are methods for use in detection of molecular residual disease. The methods may comprise deep sequencing a panel of genomic regions in cell-free DNA molecules and computer processing sequence reads to detect variants that are indicative of molecular residual disease.

公开(公告)号：US20220186323A1

公开(公告)日：2022-06-16

申请号：US17688762

申请日：2022-03-07

Applicant: GUARDANT HEALTH, INC.

Inventor： Stefanie Ann Ward MORTIMER ,  AmirAli TALASAZ ,  Darya CHUDOVA ,  Helmy ELTOUKHY

IPC: C12Q1/6886 ,  C12M1/34 ,  C12M1/00 ,  G01N33/574 ,  G16B30/10 ,  G16B20/20 ,  C12Q1/6806 ,  C12Q1/6869 ,  G16H50/30 ,  G16H50/20

Abstract: Disclosed herein are methods for use in detection of single nucleotide variants (SNVs) or indels. The methods may comprise enriching cell-free DNA molecules for a panel of genomic regions and deep sequencing the enriched cfDNA to detect the SNVs or indels.

公开(公告)号：US20210407623A1

公开(公告)日：2021-12-30

申请号：US17219338

申请日：2021-03-31

Applicant: GUARDANT HEALTH, INC.

Inventor： Oscar WESTESSON ,  Yupeng He ,  William J. GREENLEAF ,  Ariel JAIMOVICH ,  AmirAli TALASAZ

IPC: G16B30/10 ,  G16B30/00 ,  G16B20/20

Abstract: The application is directed to systems and processes to determine an estimate for tumor fraction of a sample. In various examples, amounts of methylation of nucleic acids can be determined based on a strength of binding by the nucleic acids to methyl binding domain (MBD). The nucleic acids can be partitioned according to the strength of binding to MBD. Additionally, a number of cytosine-guanine regions for the nucleic acids can be determined. Amounts of methylation of classification regions of the nucleic acids can be determined based on the partition information associated with the nucleic acids and the number of cytosine-guanine regions of the nucleic acids. The classification regions can have differing amounts of methylation in tumor cells and non-tumor cells. The estimate for tumor fraction of the sample can be determined according to the amounts of methylation of the classification regions.

公开(公告)号：US20210395836A1

公开(公告)日：2021-12-23

申请号：US17383390

申请日：2021-07-22

Applicant: GUARDANT HEALTH, INC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Scott KOPETZ ,  AmirAli TALASAZ

IPC: C12Q1/6886 ,  C07K16/28 ,  C07K16/30 ,  G16B99/00 ,  C07K14/71 ,  C07K14/82 ,  G16B20/20 ,  G16B20/10

Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.

公开(公告)号：US20210164037A1

公开(公告)日：2021-06-03

申请号：US17167974

申请日：2021-02-04

Applicant: GUARDANT HEALTH, INC.

Inventor： AmirAli TALASAZ ,  Helmy ELTOUKHY ,  Stefanie Ann Ward MORTIMER

IPC: C12Q1/6869 ,  C12Q1/6886

Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.

公开(公告)号：US20210040565A1

公开(公告)日：2021-02-11

申请号：US17000010

申请日：2020-08-21

Applicant: GUARDANT HEALTH, INC.

Inventor： Helmy ELTOUKHY ,  AmirAli TALASAZ ,  Bahram Ghaffarzadeh KERMANI ,  Nnamdi IHUEGBU

IPC: C12Q1/6886 ,  G16B30/00 ,  C12Q1/6827 ,  C12Q1/6869

Abstract: This disclosure provides, among other things, methods for generating and applying therapeutic interventions. The methods involve, for example, (a) sequencing polynucleotides from cancer cells from a subject; (b) identifying and quantifying somatic mutations in the polynucleotides; (c) developing a profile of tumor heterogeneity in the subject indicating the presence and relative quantity of a plurality of the somatic mutations in the polynucleotides, wherein different relative quantities indicates tumor heterogeneity; and (d) determining a therapeutic intervention for a cancer exhibiting the tumor heterogeneity, wherein the therapeutic intervention is effective against a cancer having the profile of tumor heterogeneity determined.